Cancer Center, Renmin Hospital of Wuhan University, Hubei, 430060, People's Republic of China.
Department of Hematology, Renmin Hospital of Wuhan University, Hubei, 430060, People's Republic of China.
Clin Transl Oncol. 2024 Jan;26(1):214-224. doi: 10.1007/s12094-023-03238-x. Epub 2023 Jun 23.
Nasal or extranasal natural killer/T-cell lymphoma (NKTCL) is a very rare aggressive lymphoma, but it is increasingly diagnosed. To evaluate some specificity by comparative analysis between primary upper aerodigestive tract (UAT) and non-upper aerodigestive tract (NUAT)NKTCL.
A retrospective analysis was performed on NKTCL patients from January 2013 to November 2022 in our cancer center.
The majority of the lesions were UAT-NKTCL 70 cases (92.1%), the primary NUAT occurred in 6 cases. Patients in the UAT group were mainly in the early stage and in the low and medium risk, while those in the NUAT group were late stage and in high risk (p = 0.000). The expressions of CD3 and TIA-1 in UAT group were higher than those in NUAT group (p = 0.031, p = 0.003), while CD7 was dominant in NUAT group (p = 0.009). For early stage NKTCL, multivariate analysis suggested that gender and PINK score were independent factors affecting PFS and OS (p < 0.05). The 3 year OS rate in initial CR group was 90.1% versus 46.4% in non-CR group (p = 0.000). In advanced stage, KI67% and bone marrow involvement were independent factors affecting OS (p = 0.022, p = 0.038).
It was difficult to distinguish between UAT and NUAT-NKTCL from histopathology. NUAT-NKTCL patients did have advanced stage and poor outcome. The prognostic value of PINK score and bone marrow involvement was proposed. We aimed to improve initial CR rates, as well as to find new predictive models to predict the whole population.
鼻型或鼻外型自然杀伤/T 细胞淋巴瘤（NKTCL）是一种非常罕见的侵袭性淋巴瘤，但近年来诊断率逐渐升高。通过比较原发上呼吸道（UAT）与非上呼吸道（NUAT）NKTCL 之间的某些特征，评估其特异性。
对 2013 年 1 月至 2022 年 11 月在我院癌症中心就诊的 NKTCL 患者进行回顾性分析。
病变多为 UAT-NKTCL 70 例（92.1%），原发于非上呼吸道 6 例。UAT 组患者主要处于早期和低、中危，而 NUAT 组患者主要处于晚期和高危（p=0.000）。UAT 组患者 CD3 和 TIA-1 的表达高于 NUAT 组（p=0.031，p=0.003），而 NUAT 组患者 CD7 占优势（p=0.009）。对于早期 NKTCL，多因素分析提示性别和 PINK 评分是影响 PFS 和 OS 的独立因素（p<0.05）。初始完全缓解（CR）组 3 年 OS 率为 90.1%，未达 CR 组为 46.4%（p=0.000）。晚期患者中，Ki67%和骨髓累及是影响 OS 的独立因素（p=0.022，p=0.038）。
从组织病理学上难以区分 UAT 和 NUAT-NKTCL。NUAT-NKTCL 患者确实处于晚期，预后不良。提出了 PINK 评分和骨髓累及的预后价值。我们旨在提高初始 CR 率，并寻找新的预测模型来预测整体人群。
